BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 26717940)

  • 1. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
    Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
    HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
    Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
    J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confinement to the intrapancreatic bile duct is independently associated with a better prognosis in extrahepatic cholangiocarcinoma.
    Ahn KS; Kang KJ; Kang YN; Kim YH; Kim TS
    BMC Gastroenterol; 2016 Feb; 16():21. PubMed ID: 26911927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma.
    Guglielmi A; Ruzzenente A; Campagnaro T; Valdegamberi A; Bagante F; Bertuzzo F; Conci S; Iacono C
    J Gastrointest Surg; 2013 Nov; 17(11):1917-28. PubMed ID: 24048613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
    Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
    BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.
    Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM
    World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of HMGA2 expression as independent poor prognostic marker in perihilar and distal cholangiocarcinoma resected with curative intent.
    Takahashi T; Kawaji H; Murakawa Y; Hayashizaki Y; Murakami T; Yabushita Y; Homma Y; Kumamoto T; Matsuyama R; Endo I
    Eur J Surg Oncol; 2021 Feb; 47(2):394-400. PubMed ID: 32878723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel three‑miRNA signature predicts survival in cholangiocarcinoma based on RNA‑Seq data.
    Cao J; Sun L; Li J; Zhou C; Cheng L; Chen K; Yan B; Qian W; Ma Q; Duan W
    Oncol Rep; 2018 Sep; 40(3):1422-1434. PubMed ID: 29956786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgery of extrahepatic bile duct cancer - current evidence and recommendations.
    Nikov A; Gürlich R
    Rozhl Chir; 2022; 101(9):416-420. PubMed ID: 36257799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma.
    Takemura Y; Ojima H; Oshima G; Shinoda M; Hasegawa Y; Kitago M; Yagi H; Abe Y; Hori S; Fujii-Nishimura Y; Kubota N; Masuda Y; Hibi T; Sakamoto M; Kitagawa Y
    Cancer Med; 2021 Aug; 10(16):5599-5613. PubMed ID: 34245137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.
    Bi C; Liu M; Rong W; Wu F; Zhang Y; Lin S; Liu Y; Wu J; Wang L
    BMC Cancer; 2019 Mar; 19(1):213. PubMed ID: 30849962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
    Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
    Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
    Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
    Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.
    Kim YH; Hong EK; Kong SY; Han SS; Kim SH; Rhee JK; Hwang SK; Park SJ; Kim TM
    Oncotarget; 2016 Apr; 7(17):23825-36. PubMed ID: 27009864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.